Angelman Syndrome Clinical Trials Angelman Syndrome RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome
Condition:   Angelman Syndrome Intervention:   Drug: NNZ-2591 Sponsor:   Neuren Pharmaceuticals Limited Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 18, 2021 Category: Research Source Type: clinical trials